You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Sanderling Ventures

BioCentury | Jun 23, 2008

Strategy

Monetizing a slice at a time

...go not to Actimis but to its shareholders. Assuming the milestones are met, majority shareholders Sanderling Ventures...

BioCentury | Mar 13, 2021

Finance

March 12 Quick Takes: Longboard, Prometheus rise after pricing IPOs; plus Monte Rosa, Nano Cures and CalciMedica

...Venture and Global Health Sciences Fund, with backing from existing investors Valence Life Sciences and Sanderling Ventures...

BioCentury | Nov 30, 2018

Financial News

ViaCyte attracts crossover investors for $80M series D

...the financing. New investors TPG Capital and RA Capital also participated, as did existing investor Sanderling Ventures...

BioCentury | Nov 29, 2018

Financial News

ViaCyte attracts crossover investors for $80M series D

...the financing. New investors TPG Capital and RA Capital also participated, as did existing investor Sanderling Ventures...

BioCentury | Oct 06, 2017

Financial News

SpecificiT completes seed financing

...Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures...
...allogeneic hematopoietic stem cell transplantation. SpecificiT also said it named Pierre Beauparlant, venture partner at Sanderling Ventures...

BioCentury | Jul 28, 2017

Financial News

PreciThera raises C$36M series A

...$28.6 million) on July 27 in an oversubscribed series A round led by Arix Bioscience. Sanderling Ventures...

BioCentury | Jul 27, 2017

Financial News

PreciThera raises C$36M in series A

...raised C$36 million ($28.6 million) in an oversubscribed series A round led by Arix Bioscience. Sanderling Ventures...

BioCentury | May 26, 2017

Finance

Europe’s bellwether challenge

...Family Office, AstraZeneca plc, other undisclosed investors DalCor Pharma U.K. Ltd. (U.K.) Series B $100.0 Sanderling Ventures...

BioCentury | Dec 01, 2016

Emerging Company Profile

Safe arrest

...Paul Scherrer Institute Corporate partners: N/A Number of employees: 3 Funds raised: Undisclosed Investors: Sanderling Ventures...

BioCentury | Nov 18, 2016

Financial News

Glycomine completes venture financing

...Glycomine raised $12 million in a series A round led by Sanderling Ventures . Chiesi Ventures and...

BioCentury | Nov 16, 2016

Financial News

Glycomine raises $12M in series A round

...Glycomine Inc. (San Francisco, Calif.) raised $12 million in a series A round led by Sanderling Ventures...

BioCentury | Apr 25, 2016

Finance

Saved by a SNP

...B round and disclosed a 2015 A round of $50 million. B round investors included Sanderling Ventures...

BioCentury | Apr 25, 2016

Finance

LPs choose Europe

...of the few that invests in Europe. The others include funds managed by Domain Associates, Sanderling Ventures...

BioCentury | Apr 20, 2016

Financial News

DalCor raises $100M in series B

...DalCor Pharma U.K. Ltd. (London, U.K.) raised $100 million in a series B round with Sanderling Ventures...

BioCentury | Oct 05, 2015

Emerging Company Profile

Picking a PCSK9

...Technology: Small molecule inhibitors of PCSK9 Disease focus: Cardiovascular Clinical status: Preclinical Founded: 2014 by Sanderling Ventures...
...IRCM Corporate partners: None Number of employees: None Funds raised: C$6.4 million ($5.6 million) Investors: Sanderling Ventures...

BioCentury | Nov 10, 2014

Company News

IRCM, Liphorus Pharmaceuticals deal

...hypercholesterolemia. IRCM said the technology directly addresses PCSK9 at the intracellular rather than extracellular level. Sanderling Ventures...

BioCentury | Nov 07, 2014

Financial News

Sanderling backs IRCM spinout Liphorus

...Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The...

BioCentury | Oct 14, 2013

Financial News

Chimerix financial update

Chimerix shareholders proposed to sell up to $50 million in shares in a secondary offering underwritten by Morgan Stanley and Cowen. Participating shareholders include Sanderling Venture Partners; New Leaf Ventures; Canaan Partners; and Alta Biopharma...

BioCentury | Sep 23, 2013

Finance

Quebec engine

...Drawn by an experienced management team and the low cost of doing business in Montreal, Sanderling Ventures...

BioCentury | Sep 09, 2013

Financial News

Sanderling Ventures financial update

...close Sanderling VII. Sanderling emphasizes early stage financing and active management of its portfolio companies. Sanderling Ventures...

BioCentury | Sep 07, 2013

Financial News

Sanderling gets $30M for Canadian fund

Sanderling Ventures secured $30 million from BDC Venture Capital and Fonds de solidarite FTQ for a Canadian fund that Sanderling said will operate in parallel to its Sanderling VII fund, which is targeting $250 million....

BioCentury | Jan 14, 2013

Financial News

Sanderling Ventures financial update

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) said it will contribute $50 million to Sanderling Ventures' new $250...
...be reached for comment, emphasizes early stage financing and active management of its portfolio companies. Sanderling Ventures...

BioCentury | Jan 11, 2013

Financial News

GSK investing in new Sanderling fund

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will contribute $50 million to Sanderling Ventures' new $250 million Sanderling...

BioCentury | Jul 30, 2012

Finance

Yes to PE; no to VC

...still held positions in New Enterprise Associates ($44 million, 1.6x); Prospect Partners ($133 million, 1.1x); Sanderling Ventures...

BioCentury | Jan 09, 2012

Finance

More knowledge, less fluff

...the potential to make countless sums of money," he said. Back then, Robert McNeil of Sanderling Ventures...

BioCentury | Jun 28, 2011

Financial News

InfraReDx raises $24.1M in series E

...device company InfraReDx Inc. (Burlington, Mass.) raised $24.1 million in a series E round from Sanderling Ventures...

BioCentury | Jan 20, 2011

Financial News

Altor raises $10.3M in D round

...$10.3 million in a series D round co-led by new investor Florida Growth Fund and Sanderling Ventures...

BioCentury | Nov 08, 2010

Finance

Blue skies for pain plays

...financings. Investors include HBM BioVentures (25.9% pre-IPO stake); MPM Capital (22.9%); OrbiMed Advisors (22.9%); and Sanderling Ventures...

BioCentury | Sep 24, 2010

Financial News

Existing investors top off Cylene's C round

...series C round, bringing the total raised in the round to $56 million. Existing investors Sanderling Ventures...

BioCentury | Aug 23, 2010

Finance

Just-in-time IPO

...from federal and state grant programs; and $15 million from a credit facility. Shareholders include Sanderling Ventures...

BioCentury | Aug 23, 2010

Finance

Taligen takes a tranche

...time, the company has chosen a new lead candidate. Investor and Chairman Tim Mills of Sanderling Ventures...

BioCentury | Apr 26, 2010

Finance

X marks the spot

Investors in oncology play Gemin X Pharmaceuticals Inc. are hoping last week's $16 million series D round, with an optional additional $4 million, will be enough to get the company through Phase IIb data. Existing...

BioCentury | Apr 21, 2010

Financial News

Gemin X raises $16 million

Gemin X Pharmaceuticals Inc. (Malvern, Pa.) raised $16 million in a series D round co-led by existing investors Caxton Advantage Life Sciences Fund and Sanderling Venture Partners. Gemin X's obatoclax is in Phase IIb testing...

BioCentury | Oct 20, 2008

Strategy

Shire's ophthalmics play

...million series A round done by Ophthotech Corp. in 2007. Timothy Mills, managing director at Sanderling Ventures...

BioCentury | Jul 01, 2008

Financial News

Gemin X raises $38 million

...The financing was led by Caxton Advantage Life Sciences Fund and Caxton Global. Existing investors Sanderling Ventures...

BioCentury | May 28, 2020

Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...to about $50 million. Existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures...

BioCentury | May 19, 2008

Company News

Fate Therapeutics management update

...Musculoskeletal, Gene/Cell therapy Hired: Paul Grayson as president and CEO, formerly a managing director at Sanderling Ventures...

BioCentury | May 16, 2008

Company News

Fate names Grayson CEO, Mendlein executive chairman

...president and CEO and John Mendlein as executive chairman. Previously, Grayson was managing director at Sanderling Ventures...

BioCentury | Dec 10, 2007

Emerging Company Profile

Corporate Profile

...Corporate partners: None Number of employees: 8 Funds raised: Not disclosed Investors: SR One and Sanderling Ventures...

BioCentury | Aug 13, 2007

Emerging Company Profile

Corporate Profile

...of South Carolina Corporate partners: None Number of employees: 4 Funds raised: $3.8 million Investors: Sanderling Ventures...

BioCentury | Apr 02, 2007

Finance

Ebb & Flow

...Blue Acquisition is a vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures...

BioCentury | Apr 02, 2007

Company News

SkyePharma, Blue Acquisition, Paul Capital Partners deal

...Acquisition is an acquisition vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures...

BioCentury | Mar 27, 2007

Company News

SkyePharma sells injectable unit, raises L14.8 million

...Acquisition is an acquisition vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures...

BioCentury | Jan 29, 2007

Tools & Techniques

Hitting RBIs

...to be acquired. HBM BioVentures Ltd. and Lilly Ventures led the series C, which included Sanderling Ventures...

BioCentury | Jan 15, 2007

Company News

SkyePharma, Blue Acquisition deal

...acquisition vehicle controlled and funded by investors including MPM Capital L.P., OrbiMed Advisors LLC and Sanderling Ventures...

BioCentury | Jan 10, 2007

Company News

SkyePharma to sell injectable unit, raise L14.8 million

...Acquisition is an acquisition vehicle controlled and funded by investors including MPM Capital; OrbiMed; and Sanderling Ventures...

BioCentury | Aug 14, 2006

Company News

Guava management update

...Business: Functional genomics, Supply/Service Hired: Donald Huffman as CFO, formerly CFO and a principal of Sanderling Ventures WIR...

BioCentury | Jul 17, 2006

Company News

Athenagen, Zapaq deal

...and CEO W. Scott Harkonen will retain his titles. Robert McNeil, a managing director at Sanderling Ventures...

BioCentury | Jul 11, 2006

Company News

Athenagen, Zapaq to merge

...Scott Harkonen will retain his positions at the newco. Robert McNeil, a managing director at Sanderling Ventures...

BioCentury | Jan 26, 2006

Company News

Watlington leaving Biosite as COO

...EVP and COO Tom Watlington will depart by the end of this quarter to join Sanderling Ventures...

BioCentury | Dec 20, 2004

Finance

Ebb & Flow

...also participated in the round. Venture tracks Donald Huffman was named CFO and principal at Sanderling Ventures...

BioCentury | Dec 15, 2004

Financial News

Sanderling names Huffman CFO

Sanderling Ventures hired Donald Huffman as CFO and principal. He replaces John Jonson who left the company to become COO of the family investment office for an individual investor. Previously, Huffman was CFO of Genteric...

BioCentury | Dec 08, 2003

Company News

BresaGen, Cythera deal

...The combined company will focus on cell therapies for CNS diseases and diabetes. BGN said Sanderling Ventures...

BioCentury | Jun 09, 2003

Company News

Cythera management update

...Diego, Calif. Business: Gene/Cell therapy Hired: Fred Middleton as acting CEO, formerly managing director at Sanderling Ventures...

BioCentury | Jun 04, 2003

Company News

CyThera names Middleton CEO

...San Diego, Calif.) named Chairman Fred Middleton as acting CEO. Middleton, a managing director of Sanderling Ventures...

BioCentury | Mar 31, 2003

Finance

Ebb & Flow

...research, and biotech analyst Mike Booth (see BioCentury, March 24). Venture tracks Paul Grayson joined Sanderling Ventures...

BioCentury | Mar 26, 2003

Financial News

Grayson joins Sanderling

...Paul Grayson joined Sanderling Ventures as a director in the firm's San Diego office. Grayson most recently...

BioCentury | Feb 24, 2003

Emerging Company Profile

Corporate Profile

...at San Diego Number of employees: 5 Funds raised: $2.2 million Investors: Asset Management; and Sanderling Ventures...

BioCentury | Oct 21, 2002

Emerging Company Profile

Corporate Profile

...$22.9 million Investors: Alloy Ventures; De Novo Ventures; Forward Ventures; Indofin; Lotus BioScience Investment Holdings; Sanderling Ventures...

BioCentury | Sep 23, 2002

Finance

Ebb & Flow

Investors voted with their feet after learning that they will have to wait even longer for regulatory clarity over competing compounds for Fabry disease from Genzyme (GENZ) and Transkaryotic (TKTX). On Friday, the FDA postponed...

BioCentury | Sep 19, 2002

Financial News

Ista raises $40 million

Ophthalmic play ISTA raised $40 million through the sale of common stock and warrants to The Sprout Group; Sanderling Venture Partners; and Investor Growth Capital. The share and warrant price is $0.38, a 31% premium...

BioCentury | Jun 11, 2002

Financial News

Favrille raises $16.9 million

...company Favrille (San Diego, Calif.) raised $16.9 million in a series B round led by Sanderling Ventures...

BioCentury | Dec 24, 2001

Emerging Company Profile

Corporate Profile

...Institute; University of Montreal; McGill University Number of employees: 30 Funds raised: US$15.6 million Investors: Sanderling Ventures...

BioCentury | Dec 24, 2001

Emerging Company Profile

Corporate Profile

...Institute; University of Montreal; McGill University Number of employees: 30 Funds raised: US$15.6 million Investors: Sanderling Ventures...

BioCentury | Oct 08, 2001

Finance

Ebb & Flow

...amount of time CEOs spend raising money. To accomplish that, the fund has brought on Sanderling Ventures...

BioCentury | May 03, 2001

Financial News

Gemin X raises $12.6 million

Gemin X raised C$19.1 million (US$12.6 million) in its second round of financing through Sanderling Venture Partners; Canadian Medical Discoveries Fund; Sofinov; BioCapital Investments; MVI Medical Venture Investments; and Business Development Bank of Canada. Gemin...

BioCentury | Jul 03, 2000

Finance

2Q Financial Markets Review: A never-ending story

...hard to visualize combinatorial chemistry synthesis or a chemical library." Robert McNeil, a partner at Sanderling Ventures...

BioCentury | May 30, 2000

Emerging Company Profile

Genteric Inc.

...Francisco and University of California Davis Number of employees: 15 Funds raised: $9.1 million Investors: Sanderling Ventures...

BioCentury | Jun 07, 1999

Company News

Vical board of directors update

...Vaccines Retired: Robert Bellas, general partner with Morgenthaler Ventures; and Fred Middleton, general partner of Sanderling Ventures WIR...

BioCentury | Jan 24, 1994

Finance

Socially conscious biomedical venture fund

...seed and early development-stage biomedical companies, largely in the western U.S., investing in parallel with Sanderling Ventures...

BioCentury | Jan 11, 1993

Finance

Biting the invisible hand

...thought to their role in the proliferation of companies looking for money. Robert McNeil of Sanderling Ventures...